Micot Pharma Passes HKEX Listing Hearing, Lead Candidate MT1013 in Phase III Clinical Trial
NewTimeSpace News: Shaanxi Micot Pharmaceutical Technology Co., Ltd. passed the Main Board listing hearing of the Hong Kong Stock Exchange on June 4, with CCB International and China Merchants Securities International as joint sponsors. As a biotech firm focusing on dual/multi-specific peptide drugs for metabolic and cardiovascular & cerebrovascular diseases, its core product MT1013 is an in-house developed dual-receptor agonist peptide under Phase III development for secondary hyperparathyroidism induced by chronic kidney disease.
NewTimeSpace News: As disclosed by HKEX, Shaanxi Micot Pharmaceutical Technology Co., Ltd. cleared its Main Board listing hearing on June 4, 2026, with CCB International and China Merchants Securities International appointed joint sponsors.
Micot is a biotechnology enterprise dedicated to the discovery, development and commercialization of dual/multi-specific peptide therapeutics targeting metabolic, cardiovascular and cerebrovascular disorders. Its flagship asset MT1013 is an independently developed dual-target receptor agonist peptide that binds to both CaSR and OGP receptors, engineered to treat secondary hyperparathyroidism complicated with chronic kidney disease. As of the latest practicable date, MT1013 has wrapped up Phase II trials and initiated Phase III study with cinacalcet as active comparator; all planned 424 subjects have completed enrollment. The Company has entered into a commercialization agreement with Everest Medicines for MT1013.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Commercial Models of Large Model Enterprises Gradually Form a Closed Loop; Orient Artificial Intelligence Theme Hybrid Fund-A (005844) Rises Over 70% Since 2026
- ChinaAMC Hang Seng Internet Technology Industry ETF(513330) Continues to Surge in Morning Trading; Tech Giants Including Tencent and Mininglamp Technology Sustainedly Intensify Investment in AI Models and Product Portfolios
